Why did Pfizer get fined 2.3 billion?

The History Behind Pfizer's Historic Fine

In 2009, pharmaceutical giant Pfizer agreed to pay a massive 2.3 billion dollars to settle civil and criminal allegations brought by the United States Department of Justice. At the time, it stood as the largest healthcare fraud settlement in U.S. history.

The core of the investigation centered on illegal marketing tactics. Federal prosecutors found that Pfizer had misbranded one of its popular painkillers, Bextra, by promoting it for uses that had not been approved by the Food and Drug Administration (FDA). Furthermore, the company pushed the off-label use of several other medications, including the antipsychotic Geodon, the antibiotic Zyvox, and the anti-epileptic drug Lyrica.

Investigators also revealed that the company utilized financial incentives to influence medical professionals. Pfizer paid illegal kickbacks to doctors—such as offering travel, paid speaking engagements, and entertainment—to encourage them to prescribe Pfizer products over competitors.

As a key component of the legal resolution, Pfizer's subsidiary, Pharmacia & Upjohn Company Inc., pleaded guilty to felony charges of misbranding the painkiller Bextra with the intent to defraud or mislead. The landmark case ultimately led to stricter corporate integrity agreements and a heightened focus on pharmaceutical marketing practices.